GBY Stock Overview
A clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Sangamo Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.38 |
| 52 Week High | US$2.92 |
| 52 Week Low | US$0.25 |
| Beta | 1.46 |
| 1 Month Change | -36.74% |
| 3 Month Change | -64.55% |
| 1 Year Change | -28.42% |
| 3 Year Change | -89.49% |
| 5 Year Change | -96.44% |
| Change since IPO | -96.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| GBY | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -39.4% | -1.6% | 0.8% |
| 1Y | -28.4% | -13.5% | 15.0% |
Return vs Industry: GBY underperformed the German Biotechs industry which returned -13.5% over the past year.
Return vs Market: GBY underperformed the German Market which returned 15% over the past year.
Price Volatility
| GBY volatility | |
|---|---|
| GBY Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: GBY's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine GBY's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 183 | Sandy Macrae | www.sangamo.com |
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A. Its preclinical development products focus on tauopathies, ALS/FTD, and huntington's diseases Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California.
Sangamo Therapeutics, Inc. Fundamentals Summary
| GBY fundamental statistics | |
|---|---|
| Market cap | €105.34m |
| Earnings (TTM) | -€70.66m |
| Revenue (TTM) | €56.70m |
Is GBY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GBY income statement (TTM) | |
|---|---|
| Revenue | US$63.76m |
| Cost of Revenue | US$101.63m |
| Gross Profit | -US$37.88m |
| Other Expenses | US$41.57m |
| Earnings | -US$79.45m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.33 |
| Gross Margin | -59.41% |
| Net Profit Margin | -124.61% |
| Debt/Equity Ratio | 0% |
How did GBY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/20 14:42 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sangamo Therapeutics, Inc. is covered by 22 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Huidong Wang | Barclays |
| Gregory Harrison | BofA Global Research |
| Jonathan Aschoff | Brean Capital |